Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a
1998

Combined Chemo-Immunotherapy for Metastatic Melanoma

Sample size: 69 publication Evidence: moderate

Author Information

Author(s): R Hoffmann, I Muller, K Neuber, S Lassmann, J Buer, M Probst, K Oevermann, A Franzke, H Kirchner, A Ganser, J Atzpodien

Primary Institution: Medizinische Hochschule Hannover

Hypothesis

The study aims to determine response rates, freedom from treatment failure, and overall survival in patients with advanced metastatic malignant melanoma treated with combined chemo-immunotherapy.

Conclusion

The combined outpatient chemo-immunotherapy regimen resulted in a 39% objective response rate and a median survival of 11 months for patients with metastatic malignant melanoma.

Supporting Evidence

  • Seven patients achieved complete remissions and 20 reached partial remissions.
  • Median survival was 11 months and median freedom from treatment failure was 5 months.
  • Patients with low-risk features had significantly better survival outcomes.

Takeaway

Doctors treated 69 patients with a mix of chemotherapy and immunotherapy for skin cancer, and many saw their cancer get better for a while.

Methodology

Patients received up to four cycles of chemotherapy followed by outpatient immunotherapy, and were evaluated on an intention-to-treat basis.

Limitations

The study did not predict freedom from treatment failure and had a small subset of long-term responders.

Participant Demographics

{"men":45,"women":24,"median_age":56,"age_range":"20-77"}

Statistical Information

P-Value

0.0002

Confidence Interval

95% confidence interval 28-52%

Statistical Significance

p<0.0005

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication